Luteolin‐Loaded Hyaluronidase Nanoparticles with Deep Tissue Penetration Capability for Idiopathic Pulmonary Fibrosis Treatment
Small Methods · 2025
DOI: 10.1002/smtd.202400980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, 2025. Verfasst von Bo Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China. Hauptthemen laut MEDLINE: Luteolin, Hyaluronoglucosaminidase, Idiopathic Pulmonary Fibrosis, Nanoparticles. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province Exploration Project, Natural Science Foundation of Zhejiang Province Public Welfare Project, Natural Science Foundation of Tianjin.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by sustained fibrotic lesions. Orally administered drugs usually fail to efficiently penetrate the interstitial tissue and reach the lesions, resulting in low treatment efficiency. Luteolin (Lut) is a natural flavonoid, active metabolites of which possess antioxidant, anti‐inflammatory, anti‐fibrotic, and anti‐apoptotic properties. In this study, a nano‐formulation is developed by loading Lut into hyaluronidase nanoparticles (Lut@HAase). These Lut@HAase nanoparticles (NPs) exhibit small size and good stability, suitable for noninvasive inhalation and accumulation in the lungs, and hyaluronidase at the site of lesions can degrade hyaluronic acid in the interstitial tissue, enabling efficient penetration of Lut. Lut's therapeutic effect, when administered via NPs, is studied both in vitro (using MRC5 cells) and in vivo (using IPF mice models), and its anti‐fibrotic properties are found to inhibit inflammation and eliminate reactive oxygen species. Conclusively, this study demonstrates that Lut@HAase can improve lung function and enhance survival rates while reducing lung damage with few abnormalities during IPF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
- Department of Pathology, Longgang Central Hospital, Shenzhen, Guangdong, 518100, China.
- State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Enginee…
ORCID-Profile: Lin Mei
Förderung
- Natural Science Foundation of Zhejiang Province Exploration Project
- Natural Science Foundation of Zhejiang Province Public Welfare Project
- Natural Science Foundation of Tianjin
- Ningbo Natural Science Foundation of China
- State Administration of Traditional Chinese Medicine and Zhejiang Provincial Administration of Traditional Chinese Medicine
- Science and Technology Research Project of colleges and universities in Hebei Province
- Medical health technology innovation project of Chinese Academy of Medical Sciences
- Key Technologies Research and Development Program
Zitieren
APA
Pan, B., Wu, F., Lu, S., Lu, W., Cao, J., Cheng, F., Ou, M., Chen, Y., Zhang, F., Wu, G., & Mei, L. (2025). Luteolin‐Loaded Hyaluronidase Nanoparticles with Deep Tissue Penetration Capability for Idiopathic Pulmonary Fibrosis Treatment. Small Methods. https://doi.org/10.1002/smtd.202400980
Vancouver
Pan B, Wu F, Lu S, Lu W, Cao J, Cheng F, et al. Luteolin‐Loaded Hyaluronidase Nanoparticles with Deep Tissue Penetration Capability for Idiopathic Pulmonary Fibrosis Treatment. Small Methods. 2025. doi:10.1002/smtd.202400980
BibTeX
@article{Pan2025,
author = {Pan, Bo and Wu, Fangping and Lu, Shanming and Lu, Wenwen and Cao, Jiahui and Cheng, Fei and Ou, Meitong and Chen, Youyi and Zhang, Fan and Wu, Guolin and Mei, Lin},
title = {Luteolin‐Loaded Hyaluronidase Nanoparticles with Deep Tissue Penetration Capability for Idiopathic Pulmonary Fibrosis Treatment},
journal = {Small Methods},
year = {2025},
doi = {10.1002/smtd.202400980}
}
EUVIMED